1. Scorecard
Verdict: BUY — SMALL.
Actionable now: Yes — accumulate at ≤ KRW 27,003 (price KRW 17,910 as of 20 October 2026).
Position: Long 16 shares, about 0.22% of portfolio NAV (20 October 2026).
2. Argument
The short version
Huons trades at roughly two-thirds of tangible book, despite owning most of the Jecheon plant that supports its injectable business. At KRW17,910 on 20 October 2026, it is below the KRW27,003 Buy-Below and remains a small BUY.
The discount has a name. The FDA found deliberate falsification of laboratory records, issued a warning letter, and placed all drugs from the plant under an import alert. Remediation is activity, not closure; the regulator has not yet accepted the system.
The ten-year history shows where the dated decision price sits. It is context for valuation, not evidence that a fallen share must rebound.
The Jecheon plant is the asset case
Huons makes generics, wellness products, local anesthetics and injectables, including for third parties. Owned plant and equipment supplies most of tangible book, but KRW218.5bn of plant (83% of PP&E) was pledged against KRW102.9bn of bank debt. A factory can remain on the balance sheet while losing its most valuable export market.
The earnings damage is already visible. First-half operating income fell 91%, the group posted a net loss, gross margin declined from 51.8% to 43.1%, and three years of aggregate free cash flow were negative as capital spending outran operating cash generation. The KRW5.28bn provision remains unexplained.
The regulatory sequence matters
Inspection findings came first; the April import alert and June warning letter are separate steps, and closure evidence is still missing.
FDA described rewritten and backdated records and judged the first corrective-action response insufficient. The company's sanctions disclosure omits the warning letter. That combination makes the repair binary: a reinspection and formal closure can reopen the North American opportunity; failure leaves an impaired factory serving a smaller market.
What the price does and does not pay for
The trailing 5.2% dividend is not pure earnings yield. Huons approved a KRW50bn capital-reserve transfer for reduction dividends and lowered its annual dividend policy to KRW800. The board also abandoned a related-party merger after shareholder opposition and a collapsing share price. The asset discount is real, but the quality-system and disclosure risks justify the Small tier.
What would change the view
Formal closure of the warning letter, a successful Jecheon reinspection and resumed North American shipments would support a re-rating. The next half-year filing should explain the KRW5.28bn provision and show whether operating profit is recovering. A failed reinspection, another provision, or a second related-party restructuring would weaken the thesis.
Sources and gaps
The report uses the half-year filing, company regulatory disclosures, the FDA warning-letter record and import alert, and the valuation history. The warning-letter page itself was not directly retrievable; its findings were cross-checked against an indexed copy and a regulatory summary. Debt covenants and segment profitability remain undisclosed.
3. Numbers that matter
Filing tangible book at 30 June 2026 was KRW27,003.53 per share. The current price is KRW17,910, Buy-Below KRW27,003, and Sell Range KRW61,565–125,311. First-half operating income fell from KRW25.9bn to KRW2.28bn and the group posted a small net loss. KRW218.5bn of plant was pledged against KRW102.9bn of bank debt. The 5.2% yield includes a KRW50bn capital-reserve transfer; the next decisive evidence is formal FDA closure.
Research only, not investment advice.